SOURCE: Research and Markets

Research and Markets

April 04, 2016 08:55 ET

Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015

Clinical Trials Are Being Instigated Across the Globe

DUBLIN, IRELAND--(Marketwired - April 04, 2016) -  Research and Markets has announced the addition of the "Cancer CD Antigens Inhibitors Therapy Market & Pipeline Insight 2015" report to their offering.

Pharmaceutical companies are continuously looking for better therapeutic options to effectively cure and prevent various malignancies. Several options for cancer treatment are available belonging to various classes of molecules. Different types of cancer have different pathophysiological characteristics due to which distinctive approach is required for effective treatment.

Clinical trials are being instigated across the globe in order to extend their utilities in different malignancies. They are versatile in nature due to which they could be used as a part of combinatorial therapy along with monoclonal antibodies. Their utilities in different malignancies are also being studied but results of such clinical trials remains elusive. They have strong clinical pipeline due to which several products would be introduced in coming years.

However, these products are at different stages of clinical pipeline and they may take long winding times as lots of experiments proving their safety and efficacy has to be done. With time more CD antigens are expected to be discovered and they would help in the increased market size. Commercial success of marketed CD antigen cancer therapeutics shows that they would be generating significant revenues in coming years.

CD antigen cancer market is expected to witness introduction of several products which will help the pharmaceutical companies to generate significant revenues. Increasing demand for better therapeutics, large unmet medical necessities and large numbers of cancer patient's patient are expected to be responsible for the growth of this market segment. Increased funding in research and development along with utilization of advanced technology will also help in increasing their market shares across the globe.

Numerous innovative CD antigen cancer therapeutics are at different stages of clinical trials which would increase their market shares. Despite these facts they have higher prices and their manufacturing is difficult but utilization of advanced technology along with streamlining of various processes are expected to overcome this barrier. In this way, future of CD antigen cancer therapeutics looks optimistic due to their superior pharmacological profiles.

Companies Mentioned:

  • ARIAD Pharmaceuticals
  • AXXO
  • Alexion Pharmaceuticals
  • AryoGen Biopharma
  • Bayer HealthCare
  • Biocad
  • Biogen
  • Biotecnol Inc.
  • Bristol-Myers Squibb
  • Chugai Pharmaceutical
  • Dr Reddy's Laboratories
  • Eisai Co Ltd
  • Emergent BioSolutions
  • Genmab
  • ImmunoGen
  • Intas Biopharmaceuticals
  • MacroGenics
  • MedImmune
  • Merck
  • Novartis
  • Ono Pharmaceutical
  • Onyx Pharmaceuticals
  • Pfizer
  • Roche
  • UCB
  • Xencor

For more information visit

Sector: Oncology

Contact Information

  • Research and Markets
    Laura Wood, Senior Manager

    For E.S.T Office Hours Call 1-917-300-0470
    For U.S./CAN Toll Free Call 1-800-526-8630
    For GMT Office Hours Call +353-1-416-8900

    U.S. Fax: 646-607-1907
    Fax (outside U.S.): +353-1-481-1716